Inozyme Pharma (NASDAQ:INZY) Upgraded by Wall Street Zen to "Sell" Rating

Inozyme Pharma (NASDAQ:INZY - Get Free Report) was upgraded by Wall Street Zen to a "sell" rating in a research note issued to investors on Saturday.

A number of other research analysts also recently issued reports on the company. Piper Sandler decreased their price target on Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. TD Cowen cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Wells Fargo & Company restated an "equal weight" rating and issued a $4.00 price objective on shares of Inozyme Pharma in a research report on Friday, May 16th. Needham & Company LLC cut Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Wedbush cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $11.75.

Inozyme Pharma Price Performance

NASDAQ:INZY remained flat at $4.00 during trading hours on Friday. Inozyme Pharma has a 52 week low of $0.72 and a 52 week high of $6.24. The stock has a market cap of $258.25 million, a PE ratio of -2.37 and a beta of 2.27. The business has a fifty day simple moving average of $3.21 and a 200 day simple moving average of $2.07. The company has a current ratio of 2.19, a quick ratio of 2.19 and a debt-to-equity ratio of 0.65.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). Analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Trading of Inozyme Pharma

Several large investors have recently made changes to their positions in INZY. Affinity Asset Advisors LLC increased its position in shares of Inozyme Pharma by 40.7% during the fourth quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock worth $11,003,000 after purchasing an additional 1,150,000 shares in the last quarter. Sanofi purchased a new stake in shares of Inozyme Pharma during the fourth quarter worth approximately $1,228,000. Renaissance Technologies LLC increased its position in shares of Inozyme Pharma by 155.7% during the fourth quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock worth $1,167,000 after purchasing an additional 256,599 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Inozyme Pharma during the fourth quarter worth approximately $658,000. Finally, Pale Fire Capital SE increased its position in shares of Inozyme Pharma by 101.7% during the first quarter. Pale Fire Capital SE now owns 440,807 shares of the company's stock worth $401,000 after purchasing an additional 222,270 shares in the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.